Tezepelumab in Patients With Eosinophilic Granulomatosis With Polyangiitis After Suboptimal Response to Anti-IL-5/5R Therapy
- PMID: 40409710
- DOI: 10.1016/j.chest.2025.05.015
Tezepelumab in Patients With Eosinophilic Granulomatosis With Polyangiitis After Suboptimal Response to Anti-IL-5/5R Therapy
Conflict of interest statement
Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: A. M. N. reports payment or honoraria for lectures and educational events from Astra Zeneca, Glaxo Smith Kline, and Sanofi and support for attending conferences from Astra Zeneca, Chiesi, and Napp. G. d’A. has worked for the advisory board work, has been engaged to provide training to HCPs on behalf of, received research grants from, and/or been sponsored to attend an educational meeting by AstraZeneca, Boehringer-Ingleheim, Chiesi, GlaxoSmithKline, NAPP, Novartis, Pfizer, Sanofi, and Teva. J. D. reports support to attend conferences from Sanofi. M. F. reports payment or honoraria for lectures from UCB and GSK. C. H. reports payment or honoraria for lectures from Sanofi, GSK, and Olympus and participation on advisory boards from Sanofi, GSK, Lilly, and Astra Zeneca and is Secretary General of the European Rhinological Society. D. J. J. reports research grants to the Department from Astra Zeneca, consulting fees from Astra Zeneca, GSK, and Sanofi Regeneron, payments or honoraria for lectures and educational events from Astra Zeneca, GSK. and Sanofi. None declared (J. G., F. H., and T. F. I.).
LinkOut - more resources
Full Text Sources
